GlassScriptPhysician profile
Brian S Navarro
NPI 1245268978
$3,228.79
in general payments reported to CMS, 2019-2025
30 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $481 · 2020: $372 · 2021: $692 · 2022: $425 · 2023: $450 · 2024: $361 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,260.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $975.07 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $757.56 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $212.73 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $194.99 | 2019-2024 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.31 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $113.03 | 2025 | Voquezna |
| Amarin Pharma, INC. | $94.28 | 2019-2021 | |
| Pfizer INC. | $87.33 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $83.50 | 2019-2021 | |
| Abbott Laboratories | $79.34 | 2022-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $52.03 | 2024 | Rexulti |
| Amgen INC. | $47.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $42.33 | 2025 | Eliquis |
| Renalytix Ai, INC. | $36.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $33.46 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $31.11 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $30.53 | 2019-2020 | |
| Esperion Therapeutics, INC. | $28.25 | 2020-2021 | |
| Gilead Sciences, INC. | $24.65 | 2019 | |
| Idorsia Pharmaceuticals US INC | $22.74 | 2022 | |
| Sanofi Pasteur INC. | $22.44 | 2025 | |
| Tactile Systems Technology INC | $20.19 | 2024 | Entre Plus, Flexitouch Plus |
| Genentech USA, INC. | $16.74 | 2019 | |
| Currax Pharmaceuticals LLC | $14.74 | 2021 | |
| Allergan, INC. | $14.52 | 2020 | |
| Antares Pharma, INC. | $14.26 | 2023 | Nocdurna, Xyosted, Tlando |
| Lilly USA, LLC | $13.89 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.83 | 2020 | |
| Avion Pharmaceuticals | $13.69 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Navarro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.